Member Interactome

New Feature: 

The BRI Member Interactome, mapping over 40 years of publications and collaborations between our researchers. 
Visit it here.

November Image of the Month

Image of the Month

Schwann Cell Art: This view is a cross section of a Schwann cell taken from a human prostate tissue. It is captured with a transmitted light microscope with phase contrast at 40X magnification at the Advanced Light Microscopy and Spectroscopy core lab at the California Nano Systems Institute. The smooth, round, inscribed curves are examples of precise and elegant nano-scale construction, providing a vital function with an aesthetic geometry.

Image by Michael Lake from the laboratory of Louis Bouchard.


Project Synapse Flyer

Attention UCLA Neuroscience Postdoctoral Scholars

You are invited to join Project Synapse, a new postdoctoral group offering a strong network of colleagues, career development workshops, and opportunities to participate in K-12 outreach and teaching activities. 

More information here.

Varghese John

Introducing the BRI's New Member


The BRI welcomes new member Varghese John, PhD. John, an associate adjunct professor of neurology and principal investigator in the department’s new Drug Discovery and Translational Laboratory. He is also co-director of the Alzehimer’s Drug Development Network. John is an accomplished medical chemist who develops new therapeutics for neurodegenerative disorders with a focus on Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Other research interests include development of new treatment approaches for traumatic brain injury, and glioblastoma multiforme. John joins UCLA from the Buck Institute for Research and Aging.

Image: John (second from left) and his drug discovery team (l to r): Jesus Campagna Barbara Jagodzinska, and Patricia Spilman.

In the News Image

In the News

Recent Discovery May Promise New Treatment to Aid Recovery After Stroke

UCLA researchers have identified a molecule that, after a stroke, signals brain tissue to form new connections to compensate for the damage and initiate repairs in the brain. BRI member S. Thomas Carmichael, MD, PhD, led the 5-year investigation which is the first to identify growth differentiation factor 10, or GDF10, a molecule that previously had no known role in the adult brain. Results are published in the October 26th edition of Nature Neuroscience, in an article entitled: "GDF10 is a signal for axonal sprouting and functional recovery after stroke." Carmichael's impact on the field was recently acknowledged by his appointment as the Carol and James Collins Chair in Neurology.

More information on the study here.

Image: Neurons (in green) are captured as they produce growth differentiation factor 10 (red)



The Interdepartmental Program for Neuroscience 


Graduate Program

Undergraduate Program

Upcoming Events



Speaker: BENJAMIN PHILPOT, PhD, Professor, Department of Cell Biology and Physiology, Neuroscience Center, Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, North Carolina
Host: STEPHANIE WHITE, PhD, Professor, Departments of Integrative Biology and Physiology, UCLA Brain Research Institute, David Geffen School of Medicine at UCLA
Title: "Pharmacogenetic Insights Into Neurodevelopmental Disorders"

12:00pm  Neuroscience Research Building (NRB) Auditorium, UCLA

Angelman syndrome (AS) is a debilitating autism spectrum disorder for which no effective treatment or cure currently exists.  AS is caused by maternal deletions or mutations of a single gene, the E3 ubiquitin ligase UBE3A.  The UBE3A is expressed monoallelically in neurons due to epigenetic silencing of the paternal allele, so losing function of the maternal allele eliminates UBE3A protein.  Motivated by this biology, we hypothesized that neural and behavioral dysfunctions associated with AS could be treated by unsilencing the intact paternal UBE3A.  Towards this goal, we developed the first-ever screen to identify small molecule compounds that can unsilence an imprinted gene.  This seminar will discuss the assay development, drug screen, target identification, and pre-clinical testing of potential AS therapeutics that arose through our novel drug discovery approach.  Additionally, the seminar will cover some of our efforts to uncover the functional role of UBE3A in the brain.



Latest Newsletter